Literature DB >> 28247313

Electronic patient-reported outcomes and toxicities during radiotherapy for head-and-neck cancer.

Joshua R Niska1, Michele Y Halyard2, Angelina D Tan3, Pamela J Atherton3, Samir H Patel1, Jeff A Sloan3.   

Abstract

PURPOSE: To characterize quality of life (QOL) using real-time, electronic patient-reported outcomes (ePROs) and to evaluate adverse events (AEs) and supportive care during head-and-neck radiotherapy (RT) and concurrent chemoradiotherapy (CCRT).
METHODS: Sixty-five patients undergoing head-and-neck RT completed electronic, real-time, 12-item linear analog self-assessments (LASA) at baseline, before biweekly appointments, and at the last week of RT. Changes in QOL domains between time points were calculated. Clinical data were collected from the institutional medical record. AEs were recorded at the same time points as the LASA and graded.
RESULTS: During head-and-neck RT, most patients had clinically meaningful decreases in all QOL domains except level of support, financial concerns, and legal concerns. QOL domains with the most prevalent, clinically meaningful decreases were fatigue (75.4% of patients; 95% CI, 62.9-84.9%), social activity (70.8%; 95% CI, 58.0-81.1%), and overall QOL (70.8%; 95% CI, 58.0-81.1%). All patients had grade 2 AEs; 35.4% had grade 3 (50.0%, CCRT; 12.0%, RT; P = .002). Weight loss averaged 5.5 kg (6.9 kg, CCRT; 2.8 kg, RT; P < .001). Intravenous hydration was needed in 52.3% (77.5%, CCRT; 12.0%, RT; P < .001); feeding tube placement 40.0% (57.5%, CCRT; 12.0%, RT; P = .001); emergency department visits without hospitalization, 10.8%; and emergent hospitalization, 27.7% (37.5%, CCRT; 12.0%, RT; P = .04).
CONCLUSIONS: Head-and-neck RT, particularly CCRT, negatively impacts patients' overall QOL, social activity, and fatigue, with frequent grade 3 AEs, weight loss, intravenous hydration, feeding tube placement, ED visits, and hospitalization. Real-time ePROs allow providers to monitor QOL at multiple time points during RT, potentially allowing early intervention to improve QOL and mitigate AEs.

Entities:  

Keywords:  Adverse events; Head-and-neck cancer; Patient-reported outcomes; Quality of life; Radiation; Toxicity

Mesh:

Year:  2017        PMID: 28247313      PMCID: PMC6301021          DOI: 10.1007/s11136-017-1528-2

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  9 in total

1.  Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial.

Authors:  Edmond H N Pow; Dora L W Kwong; Anne S McMillan; May C M Wong; Jonathan S T Sham; Lucullus H T Leung; W Keung Leung
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-15       Impact factor: 7.038

2.  Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module.

Authors:  David I Rosenthal; Tito R Mendoza; Clifton D Fuller; Katherine A Hutcheson; X Shelley Wang; Ehab Y Hanna; Charles Lu; Adam S Garden; William H Morrison; Charles S Cleeland; G Brandon Gunn
Journal:  Cancer       Date:  2014-04-07       Impact factor: 6.860

3.  Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

Authors:  Christopher M Nutting; James P Morden; Kevin J Harrington; Teresa Guerrero Urbano; Shreerang A Bhide; Catharine Clark; Elizabeth A Miles; Aisha B Miah; Kate Newbold; MaryAnne Tanay; Fawzi Adab; Sarah J Jefferies; Christopher Scrase; Beng K Yap; Roger P A'Hern; Mark A Sydenham; Marie Emson; Emma Hall
Journal:  Lancet Oncol       Date:  2011-01-12       Impact factor: 41.316

4.  Pretreatment quality of life as a prognostic factor for early survival and functional outcomes in patients with head and neck cancer.

Authors:  Chan Joo Yang; Jong-Lyel Roh; Min-Ju Kim; Sang-wook Lee; Sung-Bae Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Qual Life Res       Date:  2015-07-09       Impact factor: 4.147

5.  Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy.

Authors:  François Meyer; André Fortin; Michel Gélinas; Abdenour Nabid; François Brochet; Bernard Têtu; Isabelle Bairati
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

6.  Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy.

Authors:  Fu-Min Fang; Yi-Tien Liu; Yeh Tang; Chong-Jong Wang; Sheung-Fat Ko
Journal:  Cancer       Date:  2004-01-15       Impact factor: 6.860

7.  Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients.

Authors:  Michael K M Kam; Sing-Fai Leung; Benny Zee; Ricky M C Chau; Joyce J S Suen; Frankie Mo; Maria Lai; Rosalie Ho; Kin-yin Cheung; Brian K H Yu; Samuel K W Chiu; Peter H K Choi; Peter M L Teo; Wing-hong Kwan; Anthony T C Chan
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544

8.  Quality-of-life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): evidence from a prospective randomized study.

Authors:  Shrinivas Rathod; Tejpal Gupta; Sarbani Ghosh-Laskar; Vedang Murthy; Ashwini Budrukkar; Jaiprakash Agarwal
Journal:  Oral Oncol       Date:  2013-04-04       Impact factor: 5.337

9.  Health-related quality of life in 640 head and neck cancer survivors after radiotherapy using EORTC QLQ-C30 and QLQ-H&N35 questionnaires.

Authors:  Stephen Wan Leung; Tsair-Fwu Lee; Chih-Yen Chien; Pei-Ju Chao; Wen-Ling Tsai; Fu-Min Fang
Journal:  BMC Cancer       Date:  2011-04-12       Impact factor: 4.430

  9 in total
  5 in total

1.  Patient-reported financial toxicity and adverse medical consequences in head and neck cancer.

Authors:  Whitney H Beeler; Emily L Bellile; Keith A Casper; Elizabeth Jaworski; Nicholas J Burger; Kelly M Malloy; Matthew E Spector; Andrew G Shuman; Andrew Rosko; Chaz L Stucken; Steven B Chinn; Aleksandar F Dragovic; Christina H Chapman; Dawn Owen; Shruti Jolly; Carol R Bradford; Mark E P Prince; Francis P Worden; Reshma Jagsi; Michelle L Mierzwa; Paul L Swiecicki
Journal:  Oral Oncol       Date:  2019-12-23       Impact factor: 5.337

Review 2.  How is quality of life defined and assessed in published research?

Authors:  Daniel S J Costa; Rebecca Mercieca-Bebber; Claudia Rutherford; Margaret-Ann Tait; Madeleine T King
Journal:  Qual Life Res       Date:  2021-04-01       Impact factor: 4.147

3.  Systematic Review of Normal Tissue Complication Models Relevant to Standard Fractionation Radiation Therapy of the Head and Neck Region Published After the QUANTEC Reports.

Authors:  N Patrik Brodin; Rafi Kabarriti; Madhur K Garg; Chandan Guha; Wolfgang A Tomé
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-09-29       Impact factor: 7.038

Review 4.  Using PROMs to guide patients and practitioners through the head and neck cancer journey.

Authors:  Simon N Rogers; Brittany Barber
Journal:  Patient Relat Outcome Meas       Date:  2017-11-08

5.  Patient-reported outcomes and complications during head and neck cancer radiotherapy before versus during the COVID-19 pandemic.

Authors:  Sarah Nicole Hamilton; Nicole Chau; Eric Berthelet; Jonn Wu; Eric Tran; Melanie Chevrier; Victoria Lau; Matthew Chan; Kimberly DeVries; Vincent LaPointe; Robert A Olson
Journal:  Support Care Cancer       Date:  2021-11-26       Impact factor: 3.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.